Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.45 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10892053 | 0.88 | HPGD (0.50) | CA12CA9ALDH1A1HPGDCYP3A4 | |
| SCHEMBL17781624 | 0.82 | ALDH1A1 (0.47) | ALDH1A1HPGDCYP3A4TDP1HIF1A | |
| SCHEMBL6648245 | 0.80 | ALDH1A1 (0.57) | CA12CA9ALDH1A1HPGDCYP3A4 | |
| SCHEMBL28405015 | 0.80 | HIF1A (0.50) | CA12CA9ALDH1A1HPGDCYP3A4 | |
| SCHEMBL27638710 | 0.78 | HIF1A (0.44) | CA12CA9ALDH1A1HPGDCYP3A4 | |
| SCHEMBL29644889 | 0.78 | MAPT (0.56) | CA12CA9ALDH1A1MAPTMAOA | |
| SCHEMBL16865510 | 0.77 | RAB9A (0.56) | CA12CA9ALDH1A1HPGDCYP3A4 | |
| SCHEMBL16694459 | 0.77 | HIF1A (0.64) | ALDH1A1HIF1AEPAS1COXFA4MAPT | |
| SCHEMBL29644899 | 0.77 | PTPN1 (0.61) | CA12CA9MAOAPTPN1 | |
| SCHEMBL27212228 | 0.77 | HPGD (0.47) | CA12CA9ALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096235-B | 2, 2-dimethyl benzopyran derivative and preparation method and application thereof | 沈阳药科大学 | 2022-06-21 | — | — | CN | disclosed |
| US-9738654-B2 | Method for producing nitrogen-containing heterocyclic N-oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20150266887-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROCYCLIC N-OXIDE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-7683189-B2 | Process for producing aminobenzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| CN-100532375-C | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical containing the compound | SOLVAY PHARM GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
| CN-1894233-A | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARM GMBH (DE) | 2007-01-10 | — | — | CN | disclosed |
| US-5164509-A | BENZODIAZOLO ANALOGS | E. R. SQUIBB & SONS, INC. (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0488107-A2 | Tricyclic benzodiazole analogs and their use in the treatment of cardiovascular disorders | E.R. SQUIBB & SONS, INC. (US) | 1992-06-03 | — | — | EP | disclosed |
| US-4110347-A | ANTIHYPERTENSIVE | BEECHAM GROUP LIMITED (GB) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266887-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROCYCLIC N-OXIDE COMPOUND | NOS3, NOS2, SQOR | CA12 2350/4885CA9 1344/4885ALDH1A1 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.